Announcement of prospectus regarding the admission to trading of new shares in Recipharm issued in connection with the acquisition of Lusomedicamenta

The Board of Directors of Recipharm AB has prepared a prospectus regarding the admission to trading of newly issued class B shares on NASDAQ Stockholm. The prospectus has been approved and registered at the Swedish Financial Supervisory Authority and is now available on Recipharm’s website www.recipharm.com and at the Company’s head office, Lagervägen 7 in Jordbro, Sweden. Documents incorporated by reference in the prospectus are also available in accordance with the above.

The prospectus has been prepared due to the admission to trading of 3,500,000 new Class B shares in Recipharm, that were issued on 13 November 2014 in connection with the acquisition of Lusomedicamenta, as announced. The sellers of Lusomedicamenta have agreed to a lock-up in respect of 1,181,193 Class B shares in Recipharm until 13 November 2016.  

Shares and shareholders
The total number of shares in Recipharm amounts to 40,688,875 shares, of which 12,685,716 Class A shares and 28,003,159 Class B shares. In connection with the acquisition of the Corvette Pharmaceutical Services Group, as announced on 19 August 2014, the Company issued convertible bonds which could be converted into up to 5,030,549 Class B shares. The conversion period ends on 9 September 2015. The holders of the convertible bonds have agreed to a lock-up in respect of the new shares issued upon conversion until 14 February 20151/.

Largest shareholders (number of shares) of Recipharm as per 30 November 2014:
Flerie Participation AB2/        25.1% 
Cajelo Invest AB2/                15.7%
Lannebo fonder                   11.6%
Fjärde AP-fonden                   5.8%
SHB Fonder                           2.5%

1/ The end of the lock-up period is corrected compared to information in previous press releases related to the acquisition of the Corvette Pharmaceutical Services Group.
2/ Flerie Participation AB is controlled by Thomas Eldered, CEO and board member of Recipharm and Cajelo Invest AB is controlled by Lars Backsell, Chairman of Recipharm.

For further information please visit www.recipharm.com or contact:
Björn Westberg, CFO, ir@recipharm.com, telephone: +46 8 602 46 20

This information was submitted for publication on 22 December, 2014, at 19:15 hrs CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma through to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com.

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03
www.recipharm.com